GlassScriptPhysician profile
Manzurul A Sikder
NPI 1598885741
$99,138.76
in general payments reported to CMS, 2019-2025
42 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $32K · 2021: $19K · 2022: $6,391 · 2023: $20K · 2024: $3,229 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $2,100 · Food and Beverage: $1,620 · Education: $147 · Travel and Lodging: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,755.00 |
| Consulting Fee | $2,100.00 |
| Food and Beverage | $1,619.51 |
| Education | $147.30 |
| Travel and Lodging | $131.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $84,767.11 | 2019-2025 | Opdivo, Opdualag |
| Janssen Pharmaceuticals, INC | $6,691.26 | 2019-2021 | |
| Celgene Corporation | $4,344.55 | 2019-2023 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $463.86 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $359.17 | 2019-2024 | |
| Genentech USA, INC. | $303.07 | 2019-2025 | Phesgo, Tecentriq, Alecensa |
| Amgen INC. | $204.57 | 2019 | |
| Daiichi Sankyo INC. | $200.70 | 2023-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $193.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $153.45 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $146.87 | 2019-2020 | |
| Abbvie INC. | $119.09 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $114.98 | 2019-2025 | Ultomiris |
| Eisai INC. | $94.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manzurul Sikder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.